GNTLF (Genetic Technologies) Accounts Payable: $0.97 Mil (As of Jun. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

GNTLF Genetic Technologies Ltd GNTLF
18 GF Score
Price $1.00
View Full Analysis

What is Genetic Technologies Accounts Payable?

Genetic Technologies GNTLF 18 Accounts Payable is $0.97 Mil as of Jun. 2024. GuruFocus rates GNTLF with a GF Score™ of 18/100.

Genetic Technologies's Accounts Payable for the quarter that ended in Jun. 2024 was $0.97 Mil.

Genetic Technologies's quarterly Accounts Payable declined from Dec. 2023 ($1.28 Mil) to Mar. 2024 ($0.00 Mil) but then increased from Mar. 2024 ($0.00 Mil) to Jun. 2024 ($0.97 Mil).

Genetic Technologies's annual Accounts Payable declined from Jun. 2022 ($0.81 Mil) to Jun. 2023 ($0.56 Mil) but then increased from Jun. 2023 ($0.56 Mil) to Jun. 2024 ($0.97 Mil).

Genetic Technologies Accounts Payable Related Terms

Genetic Technologies Accounts Payable Historical Data

* Premium members only.

The historical data trend for Genetic Technologies's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genetic Technologies Accounts Payable Chart

Genetic Technologies Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Accounts Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.24 0.21 0.81 0.56 0.97

Genetic Technologies Quarterly Data
Jun19 Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 1.28 0.00 0.97 0.00
GNTLF
18GF Score
Genetic Technologies Ltd GNTLF
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Genetic Technologies Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of $0.97 Mil mean?
Genetic Technologies (GNTLF) has a Accounts Payable of $0.97 Mil as of Jun. 2024. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Genetic Technologies and its competitors.
Is Genetic Technologies' Accounts Payable too high?
Genetic Technologies' current Accounts Payable is $0.97 Mil. Overall, Genetic Technologies has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Genetic Technologies' Accounts Payable compare to LDDD and NOTV?
Genetic Technologies' Accounts Payable of $0.97 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Medical Diagnostics & Research company?
A good Accounts Payable depends on the Medical Diagnostics & Research industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Genetic Technologies and its competitors. Genetic Technologies's current Accounts Payable is $0.97 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genetic Technologies stock overvalued right now?
Genetic Technologies (GNTLF) has a current Accounts Payable of $0.97 Mil. The current Accounts Payable is $0.97 Mil. Genetic Technologies' overall GF Score™ is 18/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Genetic Technologies (GNTLF), the current Accounts Payable is $0.97 Mil as of Jun. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Genetic Technologies Business Description

Address 60-66 Hanover Street, Fitzroy, Melbourne, VIC, AUS, 3065
Genetic Technologies Ltd is an Australia-based molecular diagnostics company that offers predictive testing and assessment tools to help physicians proactively manage women's health. The company has developed BREVAGenplus which is a clinically validated risk assessment test for non-hereditary breast cancer. It also provides genetic testing services including medical testing, animal testing, forensic testing, and plant testing. The company markets BREVAGenplus to healthcare professionals in breast healthcare and imaging centers, as well as to obstetricians/ gynecologists (OBGYNs) and breast cancer risk assessment specialists. The majority of the company's revenue is generated from Australia and the United States. The group has two operating segments: EasyDNA and GeneType/Corporate.
18GF Score

Get the complete analysis for GNTLF

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.00
Price